Table 1.
Baseline characteristics of the Stockholm cohort.
| Clinical diagnosis | All groups (n = 35) | IPD (n = 25) | MSA (n = 6) | PSP (n = 4) | APS (n = 10) | p-value (IPD vs APS) |
|---|---|---|---|---|---|---|
| Gender, n (%) | ||||||
| Male | 16 (46) | 12 (48) | 3 (50) | 1 (25) | 4 (40) | 0.7 |
| Female | 19 (54) | 13 (52) | 3 (50) | 3 (75) | 6 (60) | |
| Age (y ± SD) | ||||||
| At symptom onset | 62.0 ± 9.3 | 61.4 ± 8.6 | 57.7 ± 10.6 | 71.8 ± 5.2 | 63.3 ± 11.2 | 0.6 |
| At FDG-PET | 65.9 ± 10.0 | 65.4 ± 9.6 | 61.7 ± 10.6 | 75.2 ± 6.6 | 67.1 ± 11.2 | 0.7 |
| Symptom duration, n (%) | ||||||
| < 2 years | 10 (29) | 10 (40) | 0 (0) | 0 (0) | 0 (0) | 0.03 |
| ≥ 2 years | 25 (71) | 15 (60) | 6 (100) | 4 (100) | 10 (100) | |
| Symptom duration (y ± SD) | 4.2 ± 3.4 | 4.4 ± 3.3 | 4.0 ± 2.2 | 3.5 ± 1.8 | 3.8 ± 1.9 | 0.5 |
| mH&Y score | 2.7 ± 1.0 | 2.4 ± 1.0 | 3.3 ± 0.8 | 3.8 ± 0.5 | 3.7 ± 0.7 | 0.002 |
| Comorbidities, n (%) | ||||||
| Hypertension | 13 (37) | 5 (20) | 2 (33) | 3 (75) | 5 (50) | 0.1 |
| Diabetes | 4 (11) | 2 (8) | 0 (0) | 2 (50) | 2 (20) | 0.6 |
| Dopaminergic medication (n) | 30 (86) | 22 (88) | 6 (100) | 2 (50) | 8 (80) | 0.6 |
| LEDD (mg) | 423 ± 306 | 372 ± 257 | 753 ± 314 | 250 ± 300 | 552 ± 390 | 0.2 |
| Other medications, n (%) | ||||||
| Antihypertensives | 7 (20) | 5 (20) | 0 (0) | 2 (50) | 2 (20) | 1 |
| Lipid-lowering drugs | 6 (17) | 2 (8) | 1 (17) | 3 (75) | 4 (40) | 0.04 |
| Antidiabetics | 4 (11) | 2 (8) | 0 (0) | 2 (50) | 2 (20) | 0.6 |
| Anticoagulants | 7 (20) | 2 (11) | 2 (33) | 3 (75) | 5 (50) | 0.01 |
APS atypical Parkinsonian syndromes, FDG-PET 18F-fludeoxyglucose positron emission tomography, H&Y modified Hoehn and Yahr score, IPD idiopathic Parkinson’s disease, LEDD levodopa-equivalent daily dose, MSA multiple system atrophy, PSP progressive supranuclear palsy, SD standard deviation.